Pharma stocks rose significantly on September 29, 2026, following the United States' decision to exempt certain specialty drugs from a 100% import tariff. This exemption applies to drugs imported from 20 specific jurisdictions, including India, providing relief to Indian pharmaceutical companies that export to the US market.
- Nifty Pharma index increased by over 1% during the trading session.
- Major pharma companies like Mankind Pharma, Dr Reddy’s, and Gland Pharma saw notable gains.
- The US exemption applies to specialty drugs imported from 20 jurisdictions, including India.
- Indian drugmakers qualifying for the exemption will avoid the 100% import duty on eligible medicines.
- The US remains the primary export destination for Indian pharmaceutical companies.
What caused the rise in pharma stocks on September 29, 2026?
The rise in pharma stocks was triggered by the US government's decision to exempt certain specialty drugs from a 100% import tariff. This exemption affects drugs imported from 20 jurisdictions, including India. As a result, investors saw potential growth and relief for Indian pharmaceutical companies, leading to increased buying activity in the sector.
Which pharma companies benefited from the tariff exemption?
Several pharmaceutical companies experienced gains during the trading session, including Mankind Pharma, Dr Reddy’s Laboratories, Gland Pharma, and Abbott India. These companies are part of the Nifty Pharma index, which rose by 1.01% to an intraday high of 27,032.40 points on September 29.
How did the Nifty Pharma index perform during the trading session?
The Nifty Pharma index surged by 1.01%, reaching an intraday high of 27,032.40 points. Although the index gave up some gains later in the session, it was still trading 0.43% higher at 26,876.95 points as of 10:31 am IST on September 29. This performance reflects positive investor sentiment following the tariff exemption announcement.
What is the significance of the US tariff exemption for Indian drugmakers?
The US had imposed a 100% import duty on certain patented pharmaceutical products and their ingredients, which affected many companies worldwide. However, the exemption for specialty drugs imported from 20 jurisdictions, including India, means that eligible Indian drugmakers will not have to pay this duty. This relief is significant because the US is the primary export market for Indian pharmaceutical companies, and avoiding the tariff can improve their competitiveness and profitability.
How might this exemption impact the Indian pharmaceutical industry?
The exemption is expected to provide substantial relief to Indian pharmaceutical exporters by reducing costs associated with US imports. This can lead to increased exports, higher revenues, and potentially more investment in the sector. Additionally, it may encourage Indian companies to expand their specialty drug portfolios to take advantage of the tariff exemption.
Frequently Asked Questions
Q: What types of drugs are exempt from the US 100% import tariff?
A: The exemption applies to certain specialty drugs imported from 20 specific jurisdictions, including India. These are patented pharmaceutical products and associated ingredients that qualify under the US government's criteria.
Q: Which Indian pharma companies are likely to benefit the most?
A: Companies such as Mankind Pharma, Dr Reddy’s Laboratories, Gland Pharma, and Abbott India are among those expected to benefit, as they export specialty drugs to the US market.
Q: How does the US tariff exemption affect the Indian pharmaceutical market overall?
A: The exemption reduces the cost burden on Indian exporters, potentially increasing their competitiveness in the US market. This can lead to higher export volumes and growth opportunities for the Indian pharmaceutical industry.
